4D Molecular Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(100,837) | $(107,494) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 19,665 | 17,121 |
| Vesting of common stock warrants in return for services | 88 | 87 |
| Change in fair value of derivative liability | 157 | (2) |
| Depreciation and amortization | 4,204 | 2,403 |
| Amortization of right-of-use assets | 1,545 | 1,477 |
| Net amortization (accretion) of premium (discount) on marketable securities | (1,244) | 1,059 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | — | 47 |
| Prepaid expenses and other current assets | (1,399) | 1,235 |
| Other assets | (70) | (11) |
| Accounts payable | 896 | (1,638) |
| Accrued and other liabilities | 3,371 | 2,485 |
| Deferred revenue | (715) | (3,130) |
| Operating lease liabilities | (1,453) | (324) |
| Net cash used in operating activities | (75,792) | (86,685) |
| Cash flows from investing activities | ||
| Acquisition of property and equipment | (2,771) | (11,536) |
| Purchase of marketable securities | (54,802) | (153,313) |
| Maturities of marketable securities | 173,290 | 147,799 |
| Net cash provided by (used in) investing activities | 115,717 | (17,050) |
| Cash flows from financing activities | ||
| Issuance of common stock upon offerings, net of issuance costs | 129,208 | — |
| Issuance of common stock upon exercise of stock options and warrants | 7,310 | 2,730 |
| Issuance of common stock through 2020 ESPP | 1,178 | 823 |
| Issuance of common stock for the ATM offering program, net of issuance costs | 19,136 | — |
| Payment of offering costs | — | (468) |
| Net cash provided by financing activities | 156,832 | 3,085 |
| Net increase (decrease) in cash and cash equivalents | 196,757 | (100,650) |
| Cash and cash equivalents, beginning of period | 52,351 | 153,001 |
| Cash and cash equivalents, end of period | $249,108 | $52,351 |
| Supplemental disclosures of noncash investing and financing information | ||
| Purchases of property and equipment in accounts payable and accrued and other liabilities | $234 | $937 |
| Deferred ATM costs reclassification | $468 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.